182 related articles for article (PubMed ID: 11192745)
1. Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied.
Goldberg L; Mekel J
Am J Cardiol; 2000 Dec; 86(12):1401-2. PubMed ID: 11192745
[No Abstract] [Full Text] [Related]
2. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
3. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ; Théroux P; Snapinn SM; Sax FL
Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
[TBL] [Abstract][Full Text] [Related]
4. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
6. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
[TBL] [Abstract][Full Text] [Related]
7. The glycoprotein IIb/IIIa platelet receptor blocker tirofiban, but not heparin, counteracts platelet aggregation in unstable angina pectoris.
Mattsson E; Martinsson A; Nyqvist O; Rasmanis G; Sylvén C; Karlberg KE
Am J Cardiol; 1997 Oct; 80(7):938-40. PubMed ID: 9382012
[TBL] [Abstract][Full Text] [Related]
8. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
9. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
Servoss SJ; Wan Y; Snapinn SM; DiBattiste PM; Zhao XQ; Theroux P; Jang IK; Januzzi JL;
Am J Cardiol; 2004 Apr; 93(7):843-7. PubMed ID: 15050486
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
[TBL] [Abstract][Full Text] [Related]
11. Benefit of an early invasive management strategy in women with acute coronary syndromes.
Glaser R; Herrmann HC; Murphy SA; Demopoulos LA; DiBattiste PM; Cannon CP; Braunwald E
JAMA; 2002 Dec; 288(24):3124-9. PubMed ID: 12495392
[TBL] [Abstract][Full Text] [Related]
12. Tirofiban in unstable coronary disease.
Liron M
N Engl J Med; 1998 Oct; 339(16):1163-5. PubMed ID: 9776651
[No Abstract] [Full Text] [Related]
13. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
Morrow DA; Sabatine MS; Antman EM; Cannon CP; Braunwald E; Theroux P
Am J Cardiol; 2004 Sep; 94(6):774-6. PubMed ID: 15374786
[TBL] [Abstract][Full Text] [Related]
14. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
[No Abstract] [Full Text] [Related]
16. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
van 't Hof AW; Ernst N; de Boer MJ; de Winter R; Boersma E; Bunt T; Petronio S; Marcel Gosselink AT; Jap W; Hollak F; Hoorntje JC; Suryapranata H; Dambrink JH; Zijlstra F;
Eur Heart J; 2004 May; 25(10):837-46. PubMed ID: 15140531
[TBL] [Abstract][Full Text] [Related]
17. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
18. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
Januzzi JL; Hahn SS; Chae CU; Giugliano R; Lewandrowski K; Theroux P; Jang IK
Am J Cardiol; 2000 Oct; 86(7):713-7. PubMed ID: 11018188
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-molecular-weight heparin in acute coronary syndromes.
Wallentin L
Am Heart J; 2000 Feb; 139(2 Pt 2):S29-32. PubMed ID: 10650313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
